Atara Biotherapeutics vs Fate Therapeutics
Atara Biotherapeutics is the larger business, with $121m of revenue in fiscal 2025 against $6.6m for Fate Therapeutics (18.2 times as much). Atara Biotherapeutics grew faster (-6.3% against -51.2%). Atara Biotherapeutics kept more of each dollar of sales as profit: a net margin of 27.1% against -2051.1%.
| Latest fiscal year | Atara BiotherapeuticsATRA, 2025 | Fate TherapeuticsFATE, 2025 |
|---|---|---|
| Revenue | $121m | $6.6m |
| Revenue growth | -6.3% | -51.2% |
| Net income | $32.7m | −$136m |
| Operating margin | 29.7% | -2222.4% |
| Net margin | 27.1% | -2051.1% |
| Return on equity | — | -51.8% |
| Free cash flow | −$50.9m | −$112m |
| Cash | $8.5m | $46.6m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | 161 |
| Market value | $78.8m | $236m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 2 buys, 18 sales | 0 buys, 6 sales |